⬇ Use menu for quick links ⬇
Oxulumis® is a semi-automated ocular administration device for minimally invasive delivery of retinal therapeutics, via deployment of a specially designed microcatheter into the posterior region of the suprachoroidal space. A 27-gauge needle, which accommodates variation in scleral thickness across most patients, is inserted in the pars plana of the eye. As the needle advances, the microcatheter deploys automatically once the tip of the needle reaches the suprachoroidal space, advancing posteriorly toward the macular, where the drug product will be delivered.
The Oxulumis® microcatheter is lubricious and flexible to promote advancement and employs an atraumatic (soft) tip to promote safety. The microcatheter is illuminated which allows trans-scleral visualization by direct observation, providing absolute confirmation of accurate placement of the microcatheter in the suprachoroidal space prior to administration of the drug product.
The drug product is deposited into the posterior suprachoroidal space and the natural physiological flows of the suprachoroidal space allow the drug product to migrate even more posteriorly.
The Oxulumis® device was extensively tested in animal models and is being successfully used in compassionate human cases.
Your Oxulumis microcatheterization session includes:
Case study review: Prof. Marc D de Smet, shares his human use Oxulumis experience, presenting a microcatheterization human case study and patient response.
Try out the device: use the device yourself in Oxular’s proprietary model eye, to get a more visceral understanding of the suprachoroidal microcatheterization procedure and the advantages of the Oxulumis device.
Technical exchange: Oxular senior management team will be on hand to discuss your thoughts and answer questions about the Oxulumis device and microcatheterization procedure.
“One treatment a year. Life changing.”
Oxular is developing disruptive technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally-invasive delivery. This novel combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema and age-related macular degeneration, as well as rare and orphan indications, including treatments for ocular cancers.